Thrombotic risks of oral contraceptives

@article{Rott2012ThromboticRO,
  title={Thrombotic risks of oral contraceptives},
  author={H. Rott},
  journal={Current Opinion in Obstetrics and Gynecology},
  year={2012},
  volume={24},
  pages={235–240}
}
  • H. Rott
  • Published 2012
  • Medicine
  • Current Opinion in Obstetrics and Gynecology
Purpose of review To inform about the risk of venous thromboembolism (VTE) of different hormonal contraceptives in different patient groups. Recent findings Combined oral contraceptives (COCs) differ significantly regarding VTE risk depending on amount of estrogen and type of progestogen: COCs containing desogestrol, gestoden or drospirenone in combination with ethinylestradiol (so called third-generation or fourth-generation COCs) are associated with a higher VTE risk than COCs with… Expand
Hormonal Contraceptives: Progestogen and Thrombotic Risk
TLDR
Because of the special partial effect pattern of progesterone and dydrogesterone, there is no undue thrombotic risk with these progestogens, even in combination with estrogens, and the type and the dose of the estrogens and in addition the oral and non-oral routes do have an influence. Expand
The Risk of Venous Thromboembolism with Different Generation of Oral Contraceptives; a Systematic Review and Meta-Analysis
TLDR
It seems that the risk of VTE is not same between different generations of OCs, so that third-generation has highest risk. Expand
The Risk of Venous Thromboembolism Associated with Oral Contraceptive; the Search Is Still On
TLDR
The third generation of oral contraceptive pills with lower doses of progesterone-like compounds with contraceptive efficacy was released and contain the new progestins such as Drospirenone, Norgestimate, Desogestrel and Gestodene. Expand
Isolated pulmonary embolism in a patient with progestin intrauterine device and factor V Leiden
  • Soluny Jean
  • Medicine
  • Journal of community hospital internal medicine perspectives
  • 2019
TLDR
The risk of VTE in FVL carriers seems to outweigh the benefit of contraception even when using progestin-only contraception, and non-hormonal contraception, such as copper IUD, seems to be the only safe alternative for contraception in this population. Expand
An update on new orally administered contraceptives for women
  • A. Nelson
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2015
TLDR
This article reviews the features of each of the four new oral contraceptives that have been introduced in the United States and/or Europe in the last few years and concludes that cost will continue to be the determining factor in the acceptance of these new products, unless substantial health benefits can be conclusively proven. Expand
Thrombotic risk in children undergoing orthopedic surgery.
TLDR
Thrombotic risk assessment scores - which are based on expert opinion and large VTE registers but have not been evaluated in clinical studies - are currently the most reliable method to evaluate the thromBotic risk in children and to prescribe thromboprophylaxis. Expand
Use of oral contraceptives in three European countries: a population-based multi-database study
  • I. Bezemer, K. Verhamme, +6 authors R. Herings
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2016
TLDR
Assessment of health care databases of three European countries found second-generation OCs were most frequently prescribed in the Netherlands, and in the UK, and even more so in Italy, many women used third- or fourth- generation OCs. Expand
Contraception in Patients with Rheumatic Disease.
Contraception represents an important area of reproductive health for patients with rheumatic diseases given the potential pregnancy risks associated with active disease, teratogenic medications, andExpand
Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism
TLDR
Multicenter, prospective studies are needed to identify and confirm risk factors for pediatric VTE in order to create a pediatric risk-assessment tool and optimize preventive measures and reduce unintended harm. Expand
Pregnancy and Autoimmune Disease, Reproductive and Hormonal Issues
TLDR
With improvements in the monitoring and management of SLE, women with the disease have less functional impairments, end-organ damage, or reduced life expectancy; therefore, they increasingly feel healthy enough to bear and raise children. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 18 REFERENCES
Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
TLDR
The risk of nonfatal VTE for the contraceptive patch is similar to the risk for OCs containing 35 microg ethinylestradiol and norgestimate, an OC that has been marketed for over a decade. Expand
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
TLDR
A high risk of venous thrombosis during the first months of oral contraceptive use irrespective of the type of oral contraceptives is confirmed, and many women do not use the safest brands. Expand
Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.
TLDR
It is advocated that detailed counseling on all contraceptive options, including COCs, is provided, addressing the associated risks of both VTE and unintended pregnancy, enabling these women to make an informed choice. Expand
Third generation oral contraceptives and risk of venous thrombosis: meta-analysis
TLDR
This meta-analysis supports the view that thirdgeneration oral contraceptives are associated with an increased risk of venous thrombosis compared with second generation oral contraceptives, and cannot be explained by several potential biases. Expand
The Risk of Deep Venous Thrombosis Associated With Injectable Depot–Medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine Device
TLDR
The risk of venous thrombosis was increased for injectable depot–medroxyprogesterone acetate contraceptive users, while the authors were able to reliably exclude an increased risk associated with levonorgestrel intrauterine device use. Expand
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor
TLDR
It is observed that the differences in APC resistance induced by OC containing different progestogens can at least in part be explained by different effects of OC on free protein S and TFPI. Expand
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
TLDR
The NOMAC/E2 pill regimen has fewer adverse effects on blood biological coagulation and fibrinolysis markers than LNG/EE, and could have a more favourable venous thromboembolism risk profile than Lng/EE. Expand
Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study.
TLDR
Evidence is provided that the customary effects of combined hormonal contraceptives on hemostatic variables and estrogen-sensitive liver proteins are largely related to EE and independent of delivery route during short-term treatment. Expand
Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism
  • U. Ågren, Marjatta Anttilat, +4 authors E. Mommers
  • Medicine
  • The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • 2011
TLDR
The monophasic COC NOMAC/E2 had less influence on haemostasis, lipids and carbohydrate metabolism than the COC LNG/EE. Expand
The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism
TLDR
It can be concluded that the POP containing 75 μg desogestrel has a negligible effect on lipid metabolism, Despite the higher progestogen dose, the effect of this new POP is similar to that of a traditional POP containing 30 μg levonorgestrel. Expand
...
1
2
...